en · de · es · fr · pt
sr9009-notes.peptides6155.com › Faq › Analytical Detection And Storage — Practical Notes

Analytical Detection And Storage — Practical Notes

By Editorial Desk · published 2025-11-06 · last reviewed 2025-12-05 · Faq

LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-12-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Sr9009 at a glance

PropertyValueNotes
Typical storage temperature-20 °C or lowerDesiccated and protected from light
Common analytical methodLC-MS/MSDetects parent drug and metabolites
Solubility classLipophilic; soluble in organic solventsLow aqueous solubility
Molecular weight437.94 g/molCalculated from reported formula
SynonymsSR9009; REV-ERB agonistCode name used in scientific literature

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

Related pages on this site

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Reference notes

=== Kinetics === The two forms of inorganic arsenic, reduced (trivalent As(III)) and oxidized (pentavalent As(V)), can be absorbed and accumulated in tissues and body fluids. In the liver, the metabolism of arsenic involves enzymatic and non-enzymatic methylation; the most frequently excreted metabolite (≥ 90%) in the urine of mammals is dimethylarsinic acid or cacodylic acid, DMA(V). Dimethylarsenic acid is also known as Agent Blue and was used as herbicide in the American war in Vietnam. In humans, inorganic arsenic is reduced nonenzymatically from pentoxide to trioxide, using glutathione, or it is mediated by enzymes. Reduction of arsenic pentoxide to arsenic trioxide increases its toxicity and bioavailability. Methylation occurs through methyltransferase enzymes. S-adenosylmethionine (SAM) may serve as a methyl donor. Various pathways are used, the principal route being dependent on the current cellular environment. Resulting metabolites are monomethylarsonous acid, MMA(III), and dimethylarsinous acid, DMA(III). Methylation had been regarded as a detoxification process, but reduction from +5 As to +3 As may be considered as a bioactivation instead. Another suggestion is that methylation might be a detoxification if "As[III] intermediates are not permitted to accumulate" because the pentavalent organoarsenics have a lower affinity to thiol groups than inorganic pentavalent arsenics. Gebel (2002) stated that methylation is a detoxification through accelerated excretion.

=== Compounded versions === In the US, compounding pharmacies may prepare compounded versions of a drug on the Food and Drug Administration's (FDA) drug shortages list if the compounded drug meets certain conditions detailed in federal law. The FDA declared a shortage for Ozempic and Wegovy (but not Rybelsus) starting in August 2022. As of January 2026, there were up to 1.5 million users of compounded GLP-1 drugs (including semaglutide) in the United States, according to Novo Nordisk CEO Mike Doustdar. Some compounded versions contain salts of semaglutide, including the sodium and the acetate. The FDA cautioned that formulations containing semaglutide sodium or semaglutide acetate had not yet been shown to be safe and effective, and stated that moreover, the FDA does not evaluate compounded drugs for safety and effectiveness. The National Association of Boards of Pharmacy, a trade organization for pharmacy regulators, claims that there are tens of thousands of online pharmacies operating illegally or outside of the association's recommendations. Novo Nordisk has taken legal action against several businesses that it alleges are selling unfit semaglutide products.

One of the increasingly used methods includes the use of LA-ICP-MS. In LA-ICP-MS, a laser beam is focused on a sample surface, causing it to vaporize and form a high-temperature plasma. This plasma is then introduced into an inductively coupled plasma (ICP) source, where further ionization and excitation occur. The resulting ions are then analysed using a mass spectrometer (MS).

== Second island chain == The second island chain, also called the "second island cloud" by Earl Hancock Ellis, has two different interpretations, but the version most commonly used refers to the island chain which is formed by Japan's Bonin Islands and Volcano Islands, in addition to the Mariana Islands (most notably Guam, an unincorporated American overseas territory with a heavily fortified military base), western Caroline Islands (Yap and Palau), and extends to Western New Guinea. The chain serves as the eastern maritime boundary of the Philippine Sea. As it is located within the middle portion of the West Pacific, it acts as a second strategic defense line for the United States.

The attitude that Mexico takes in the present eventuality is based on the fact that our determination stems from a need for legitimate defense. We know the limits of our military resources and we know that, given the enormity of the international masses in conflict, our role in the current conflict will not consist of extra-continental war actions, for which we are not prepared. "Simulated neutrality" had been left behind and Mexico was explicitly on the side of the Allies as a belligerent country. Lázaro Cárdenas was appointed Secretary of Defense, the National Military Service (SMN) was created, the United States delivered armaments to improve the capacity of the Mexican army, and the properties of German, Japanese and Italian citizens were seized. Even so, Avila Camacho indicated that Mexico's role in the conflict was not on the battlefield, but to prepare his defenses and provide resources to its new allies. Between June and September 1942 the U-Boats sank four more ships: Tuxpam, Las Choapas, Oaxaca and Amatlán. In view of this situation, the United States, under the pretext of the possibility of aggression by Japan on the coasts of the Pacific Ocean, began discreet negotiations to be allowed to install a military base on the Baja California peninsula; according to historian Humberto Musacchio, that there was speculation that he might have tried to occupy that part of Mexican territory without success.

Sources: en.wikipedia.org

Reference notes

=== Blood-feeding insects === Many blood-feeding insects like horseflies or mosquitoes inject multiple bioactive compounds into their prey. These insects have been used by practitioners of Eastern Medicine for hundreds of years to prevent blood clot formation or thrombosis. However, modern medical research has only recently begun to investigate the drug development potential of blood-feeding insect saliva. These compounds in the saliva of blood feeding insects are capable of increasing the ease of blood feeding by preventing coagulation of platelets around the wound and provide protection against the host's immune response. Currently, over 1280 different protein families have been associated with the saliva of blood feeding organisms.

NMNAT3 is localized in mitochondria or cytoplasm, depending upon the cell type. Knockdown of NMNAT3 gene expression in cell culture strongly reduces mitochondrial function. NMNAT3 is essential for maintaining NAD in red blood cells. The catechin epigallocatechin gallate found in tea can activate NMNAT3 by more than 40%. Until January 2026, mutations in the NMNAT3 gene had not been associated with any known human disease, although it had been discovered that NMNAT3 deficiency causes hemolytic anemia in mice. In January 2026, researchers at the University Medical Center Utrecht in Utrecht, The Netherlands, were the first to link NMNAT3 deficiency to disease in vivo, in a patient with unexplained hereditary hemolytic anemia. The patient was successfully treated by supplementing NAD.

To revitalize the economy, from 1971 the Gierek regime introduced wide-ranging reforms that involved large-scale foreign borrowing. These actions initially caused improved conditions for consumers, but in a few years the strategy backfired and the economy deteriorated. Another attempt to raise food prices resulted in the June 1976 protests. The Workers' Defence Committee (KOR), established in response to the crackdown that followed, consisted of dissident intellectuals determined to support industrial workers, farmers and students persecuted by the authorities. The opposition circles active in the late 1970s were emboldened by the Helsinki Conference processes. In October 1978, the Archbishop of Kraków, Cardinal Karol Józef Wojtyła, became Pope John Paul II, head of the Catholic Church. Catholics and others rejoiced at the elevation of a Pole to the papacy and greeted his June 1979 visit to Poland with an outpouring of emotion. Fueled by large infusions of Western credit, Poland's economic growth rate was one of the world's highest during the first half of the 1970s, but much of the borrowed capital was misspent, and the centrally planned economy was unable to use the new resources effectively. The 1973 oil crisis caused recession and high interest rates in the West, to which the Polish government had to respond with sharp domestic consumer price increases. The growing debt burden became insupportable in the late 1970s, and negative economic growth set in by 1979.

The new owners turned the company around by closing more underperforming locations, changing the company's marketing strategy, and by introducing new products on a regular basis. After four years, Arby's was able to issue $300 million in dividends, which resulted in Wendy's receiving $54.9 million for its minority stake with the remainder paid to Roark. In February 2017, Arby's investigated a malware attack on its payment system that targeted thousands of customer credit and debit cards. The malware was placed on point-of-sale systems inside Arby's corporate-owned restaurants, not its locations owned by franchisees, and was active between October 25, 2016, and January 19, 2017. Eight credit unions and banks from Alabama, Arkansas, Indiana, Louisiana, Michigan, Pennsylvania and Montana have filed suit since early February against Arby's concerning the data breach. In September 2017, Arby's returned to Kuwait for the first time in two decades by the opening of an Arby's franchise in Jabriya by Kharafi Global. In November 2017, Arby's announced it had negotiated a purchase for the restaurant chain Buffalo Wild Wings for $2.4 billion in cash. As part of this acquisition, the parent was renamed from Arby's Restaurant Group, Inc. to Inspire Brands. In October 2018, Arby's expanded into the North African country of Egypt by opening three restaurants in the capital city of Cairo with the help of local franchise partner Vantage Egypt Tourism and Entertainment.

Sources: en.wikipedia.org

Notes from published material

Light: daylength and photoperiod for regulating circadian and seasonal rhythms Olfactory stimuli, including pheromones Steroids, including gonadal steroids and corticosteroids Neurally transmitted information arising in particular from the heart, enteric nervous system (of the gastrointestinal tract), and the reproductive tract. Autonomic inputs Blood-borne stimuli, including leptin, ghrelin, angiotensin, insulin, pituitary hormones, cytokines, plasma concentrations of glucose and osmolarity etc. Stress Invading microorganisms by increasing body temperature, resetting the body's thermostat upward.

=== Secondary literature === Johns, Michael (5 November 1989). "Namibian Voters Deny Total Power to SWAPO. [Reprint]". barrysgovsites.blogspot.com. The Wall Street Journal, original publisher. Retrieved 7 November 2024. van der Hoog, Tycho (June 2022). "A New Chapter in Namibian History: Reflections on Archival Research". History in Africa. 49. Cambridge University Press: 389–414. doi:10.1017/hia.2021.12. hdl:1887/3303534. Retrieved 7 November 2024. An explainer of existing archives on SWAPO.

This was followed in 1947 by the widespread introduction of methadone, another structurally unrelated compound with pharmacological properties similar to those of morphine. After World War I, further advances were made in the field of intratracheal anesthesia. Among these were those made by Sir Ivan Whiteside Magill (1888–1986). Working at the Queen's Hospital for Facial and Jaw Injuries in Sidcup with plastic surgeon Sir Harold Gillies (1882–1960) and anesthetist E. Stanley Rowbotham (1890–1979), Magill developed the technique of awake blind nasotracheal intubation. Magill devised a new type of angulated forceps (the Magill forceps) that are still used today to facilitate nasotracheal intubation in a manner that is little changed from Magill's original technique. Other devices invented by Magill include the Magill laryngoscope blade, as well as several apparatuses for the administration of volatile anesthetic agents. The Magill curve of an endotracheal tube is also named for Magill. The first hospital anesthesia department was established at the Massachusetts General Hospital in 1936, under the leadership of Henry K. Beecher (1904–1976). Beecher, who received his training in surgery, had no previous experience in anesthesia. Although initially used to reduce the sequelae of spasticity associated with electroconvulsive therapy for psychiatric disease, curare found use in the operating rooms at Bellvue by E.M. Papper and Stuart Cullen in the 1940s using preparations made by Squibb.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

How should SR9009 be stored?

Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.

What purity methods are used?

High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Network